{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:02:46Z","timestamp":1780822966705,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies are myositis-specific autoantibodies that have been identified in a subset of patients with interstitial pneumonia who do not present with dermatomyositis or polymyositis. Anti-ARS antibody-positive interstitial pneumonia is commonly treated with steroids or immunosuppressive agents and is usually responsive to these therapies. Here, we present in detail a case in which respiratory failure of a patient diagnosed with anti-ARS antibody-positive interstitial pneumonia was exacerbated by treatment with steroids and immunosuppressive agents. Further examination revealed misdiagnosis of this patient and a subsequent diagnosis of autoimmune pulmonary alveolar proteinosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 66-year-old man presented to the hospital with dyspnea on exertion, which resulted in the detection of interstitial pneumonia. Serum anti-ARS antibodies were detected; however, there were no other findings suggestive of myositis. Pulmonary alveolar proteinosis (PAP) was suspected based on the marked increase in serum KL-6 and chest computed tomography findings. The bronchoalveolar lavage revealed no milky changes in the lavage fluid. After treatment with steroids and initiation of immunosuppressive agents for anti-ARS antibody-positive interstitial pneumonia, respiratory failure and chest imaging findings showed worsening of the condition. Bronchoscopy was repeated, and milk-like alveolar lavage fluid was collected; serum anti-granulocyte macrophage colony-stimulating factor antibody was identified. Steroids and immunosuppressive agents were gradually tapered and discontinued, and the patient\u2019s condition stabilized after repeated alveolar lavage under general anesthesia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Due to similar presentation, PAP can be misdiagnosed as interstitial pneumonia. If pulmonary lesions due to interstitial pneumonia are exacerbated by immunosuppressive treatment, physicians should reconsider the diagnosis and include PAP in the differential diagnosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-01909-z","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:03:19Z","timestamp":1648728199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Autoimmune pulmonary alveolar proteinosis exacerbated by steroid therapy due to misdiagnosis as anti-aminoacyl-tRNA synthetase (ARS) antibody positive- interstitial pneumonia: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Hiroshi","family":"Ishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7577-476X","authenticated-orcid":false,"given":"Noriho","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Yura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Obase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ishimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"1909_CR1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood-2003-05-1565","volume":"103","author":"K Uchida","year":"2004","unstructured":"Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004;103:1089\u201398.","journal-title":"Blood"},{"key":"1909_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1164\/rccm.200708-1271OC","volume":"177","author":"Y Inoue","year":"2008","unstructured":"Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752\u201362.","journal-title":"Am J Respir Crit Care Med"},{"key":"1909_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/resp.13831","volume":"25","author":"S Jouneau","year":"2020","unstructured":"Jouneau S, M\u00e9nard C, Lederlin M. Pulmonary alveolar proteinosis. Respirology. 2020;25:816\u201326.","journal-title":"Respirology"},{"key":"1909_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1816216","volume":"381","author":"R Tazawa","year":"2019","unstructured":"Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, et al. Inhaled GM-CSF for pulmonary alveolar proteinosis. N Engl J Med. 2019;381:923\u201332.","journal-title":"N Engl J Med"},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2017.10.020","volume":"132","author":"H Yura","year":"2017","unstructured":"Yura H, Sakamoto N, Satoh M, Ishimoto H, Hanaka T, Ito C, et al. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. Respir Med. 2017;132:189\u201394.","journal-title":"Respir Med"},{"key":"1909_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","volume":"127","author":"K Tanizawa","year":"2017","unstructured":"Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017;127:57\u201364.","journal-title":"Respir Med"},{"key":"1909_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3899\/jrheum.180778","volume":"46","author":"H Hozumi","year":"2019","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, et al. Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis. J Rheumatol. 2019;46:509\u201317.","journal-title":"J Rheumatol"},{"key":"1909_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1164\/rccm.2109105","volume":"166","author":"JF Seymour","year":"2002","unstructured":"Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215\u201335.","journal-title":"Am J Respir Crit Care Med"},{"key":"1909_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1046\/j.1365-2567.1999.00806.x","volume":"97","author":"A Meager","year":"1999","unstructured":"Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J, et al. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology. 1999;97:526\u201332.","journal-title":"Immunology"},{"key":"1909_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/jcm9051356","volume":"9","author":"E Ramos-Martinez","year":"2020","unstructured":"Ramos-Martinez E, Falf\u00e1n-Valencia R, P\u00e9rez-Rubio G, Mejia M, Buend\u00eda-Rold\u00e1n I, Gonz\u00e1lez-P\u00e9rez MI, et al. Anti-Aminoacyl transfer-RNA-synthetases (Anti-tRNA) autoantibodies associated with interstitial lung disease: pulmonary disease progression has a persistent elevation of the Th17 cytokine profile. J Clin Med. 2020;9:1356.","journal-title":"J Clin Med."},{"key":"1909_CR11","doi-asserted-by":"publisher","first-page":"e25816","DOI":"10.1097\/MD.0000000000025816","volume":"100","author":"M Jiang","year":"2021","unstructured":"Jiang M, Dong X, Zheng Y. Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies. Medicine (Baltimore). 2021;100:e25816.","journal-title":"Medicine (Baltimore)"},{"key":"1909_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.023","volume":"152","author":"S Shioya","year":"2019","unstructured":"Shioya S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, et al. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia. Respir Med. 2019;152:44\u201350.","journal-title":"Respir Med"},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12890-015-0085-0","volume":"15","author":"K Akasaka","year":"2015","unstructured":"Akasaka K, Tanaka T, Kitamura N, Ohkouchi S, Tazawa R, Takada T, et al. Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. BMC Pulm Med. 2015;15:88.","journal-title":"BMC Pulm Med"},{"key":"1909_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3109\/14397595.2016.1153443","volume":"28","author":"Y Imura","year":"2018","unstructured":"Imura Y, Yukawa N, Handa T, Nakashima R, Murakami K, Yoshifuji H, et al. Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. Mod Rheumatol. 2018;28:724\u20139.","journal-title":"Mod Rheumatol"},{"key":"1909_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12890-020-1110-5","volume":"20","author":"S Sato","year":"2020","unstructured":"Sato S, Akasaka K, Ohta H, Tsukahara Y, Kida G, Tsumiyama E, et al. Autoimmune pulmonary alveolar proteinosis developed during immunosuppressive treatment in polymyositis with interstitial lung disease: a case report. BMC Pulm Med. 2020;20:84.","journal-title":"BMC Pulm Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-01909-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:06:51Z","timestamp":1648728411000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-01909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-01909-z","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have received written consent for publication from the patient involved in the case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}